Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sgi-1776. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 known ✓ | P11309 | 19/20 | 1.00 |
| ▸ | PIM3 known ✓ | Q86V86 | 2/20 | 1.00 |
| ▸ | PIM2 known ✓ | Q9P1W9 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 1/20 | 1.00 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 1/20 | 1.00 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 1.00 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 1.00 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sgi-1776 SCHEMBL29353896 | 1.00 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| Sgi-1776 SCHEMBL19923098 | 0.96 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| Sgi-1776 SCHEMBL29401822 | 0.96 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL140271 | 0.93 | PIM1 (0.89) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL103050 | 0.91 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102377 | 0.91 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102154 | 0.91 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102700 | 0.89 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102535 | 0.89 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL22421445 | 0.89 | PIM1 (0.80) | PIM1KCNH2FLT3PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | claimed |
| WO-2025125504-A1 | COMBINED AGENTS WITH SYNERGISTIC EFFECTS AGAINST GLIOMAS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2025-06-19 | — | — | WO | claimed |
| EP-4570246-A1 | COMBINED AGENTS WITH SYNERGISTIC EFFECTS AGAINST GLIOMAS | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2025-06-18 | — | — | EP | claimed |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-04-24 | — | — | US | claimed |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2025-03-13 | — | — | US | claimed |
| EP-3908281-B9 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING MULTIPLE MYELOMA | CELGENE CORP (US) | 2024-10-16 | — | — | EP | claimed |
| EP-3908281-B1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING MULTIPLE MYELOMA | CELGENE CORP (US) | 2024-07-31 | — | — | EP | claimed |
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| EP-3021862-B1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2017-08-30 | — | — | EP | claimed |
| US-20160166632-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2016-06-16 | — | — | US | claimed |
| EP-3021862-A2 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | Onyx Therapeutics, Inc. (US) | 2016-05-25 | — | — | EP | claimed |
| EP-2086979-B1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2015-06-03 | — | — | EP | claimed |
| WO-2015009888-A2 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS, INC. (US) | 2015-01-22 | — | — | WO | claimed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | claimed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | claimed |
| EP-2086979-A2 | IMIDAZOÝ1,2-B¨PYRIDAZINE AND PYRAZOLOÝ1,5-A¨PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SuperGen, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | claimed |
| WO-2008058126-A2 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | PIM1 103/4885PIM3 202/4885PIM2 126/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | PIM1 103/4885PIM3 202/4885PIM2 126/4885 |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20160166632-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | PIM3, PIM1, PIM2 | PIM1 2/4885PIM3 1/4885PIM2 3/4885 |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | NEK4, AURKB, XPO1 | PIM1 10/4885PIM3 37/4885PIM2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.